The PE Ratio as of December 2024 (TTM) for Kura Oncology, Inc. (KURA) is -3.80

According to Kura Oncology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.80. This represents a change of -53.34% compared to the average of -8.14 of the last 4 quarters.

Kura Oncology, Inc. (KURA) Historical PE Ratio (quarterly & annually)

How has KURA PE Ratio performed in the past?

The mean historical PE Ratio of Kura Oncology, Inc. over the last ten years is -7.48. The current -3.80 PE Ratio has changed 4.98% with respect to the historical average. Over the past ten years (40 quarters), KURA's PE Ratio was at its highest in in the June 2016 quarter at -1.89. The PE Ratio was at its lowest in in the December 2014 quarter at -1967.47.

Kura Oncology, Inc. (KURA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Kura Oncology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kura Oncology, Inc. (KURA) Average PE Ratio

How has KURA PE Ratio performed in the past?

The current PE Ratio of Kura Oncology, Inc. (KURA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Kura Oncology, Inc. (KURA) PE Ratio vs. Peers

How is KURA’s PE Ratio compared to its peers?

Kura Oncology, Inc.’s PE Ratio is less than Protagonist Therapeutics, Inc. (14.68), greater than Merus N.V. (-11.85), greater than Replimune Group, Inc. (-4.55), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), less than KalVista Pharmaceuticals, Inc. (-2.64), greater than Crinetics Pharmaceuticals, Inc. (-15.55), greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than Viridian Therapeutics, Inc. (-5.08), greater than Gracell Biotechnologies Inc. (-29.26), greater than Monte Rosa Therapeutics, Inc. (-4.90), greater than Design Therapeutics, Inc. (-7.36), greater than Erasca, Inc. (-4.40), less than Cogent Biosciences, Inc. (-3.53), greater than Larimar Therapeutics, Inc. (-3.90), greater than Kiniksa Pharmaceuticals, Ltd. (-160.17), greater than Day One Biopharmaceuticals, Inc. (-14.55), less than Inozyme Pharma, Inc. (-1.97), less than Zentalis Pharmaceuticals, Inc. (-1.26), greater than Syndax Pharmaceuticals, Inc. (-3.83),

Build a custom stock screener for Kura Oncology, Inc. (KURA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kura Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kura Oncology, Inc. (KURA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kura Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.